These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27414797)

  • 1. Novel Bioluminescent Binding Assays for Ligand-Receptor Interaction Studies of the Fibroblast Growth Factor Family.
    Song G; Shao XX; Wu QP; Xu ZG; Liu YL; Guo ZY
    PLoS One; 2016; 11(7):e0159263. PubMed ID: 27414797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel bioluminescent receptor-binding assays for peptide hormones: using ghrelin as a model.
    Liu Y; Shao XX; Zhang L; Song G; Liu YL; Xu ZG; Guo ZY
    Amino Acids; 2015 Oct; 47(10):2237-43. PubMed ID: 26002812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bioluminescent binding assays for interaction studies of protein/peptide hormones with their receptors.
    Liu YL; Guo ZY
    Amino Acids; 2016 May; 48(5):1151-60. PubMed ID: 27020777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid preparation of bioluminescent tracers for relaxin family peptides using sortase-catalysed ligation.
    Wang JH; Shao XX; Hu MJ; Wei D; Nie WH; Liu YL; Xu ZG; Guo ZY
    Amino Acids; 2017 Sep; 49(9):1611-1617. PubMed ID: 28631012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quick preparation of nanoluciferase-based tracers for novel bioluminescent receptor-binding assays of protein hormones: Using erythropoietin as a model.
    Song G; Wu QP; Xu T; Liu YL; Xu ZG; Zhang SF; Guo ZY
    J Photochem Photobiol B; 2015 Dec; 153():311-6. PubMed ID: 26506452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoluciferase as a novel quantitative protein fusion tag: Application for overexpression and bioluminescent receptor-binding assays of human leukemia inhibitory factor.
    He SX; Song G; Shi JP; Guo YQ; Guo ZY
    Biochimie; 2014 Nov; 106():140-8. PubMed ID: 25179300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ultrasensitive bioluminescent receptor-binding assay of INSL3 through chemical conjugation with nanoluciferase.
    Zhang L; Song G; Xu T; Wu QP; Shao XX; Liu YL; Xu ZG; Guo ZY
    Biochimie; 2013 Dec; 95(12):2454-9. PubMed ID: 24056075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the novel bioluminescent ligand-receptor binding assay to relaxin-RXFP1 system for interaction studies.
    Wu QP; Zhang L; Shao XX; Wang JH; Gao Y; Xu ZG; Liu YL; Guo ZY
    Amino Acids; 2016 Apr; 48(4):1099-1107. PubMed ID: 26767372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioluminescent Ligand-Receptor Binding Assays for Protein or Peptide Hormones.
    Liu YL; Guo ZY
    Methods Mol Biol; 2016; 1461():65-90. PubMed ID: 27424896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel BRET-based binding assay for interaction studies of relaxin family peptide receptor 3 with its ligands.
    Wang JH; Shao XX; Hu MJ; Wei D; Liu YL; Xu ZG; Guo ZY
    Amino Acids; 2017 May; 49(5):895-903. PubMed ID: 28161795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
    Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
    Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2.
    Safran M; Eisenstein M; Aviezer D; Yayon A
    Biochem J; 2000 Jan; 345 Pt 1(Pt 1):107-13. PubMed ID: 10600645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element.
    Newberry EP; Willis D; Latifi T; Boudreaux JM; Towler DA
    Mol Endocrinol; 1997 Jul; 11(8):1129-44. PubMed ID: 9212060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
    Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand dependent and independent internalization and nuclear translocation of fibroblast growth factor (FGF) receptor 1.
    Reilly JF; Mizukoshi E; Maher PA
    DNA Cell Biol; 2004 Sep; 23(9):538-48. PubMed ID: 15383174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity.
    Ibrahimi OA; Zhang F; Eliseenkova AV; Linhardt RJ; Mohammadi M
    Hum Mol Genet; 2004 Jan; 13(1):69-78. PubMed ID: 14613973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex.
    Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL
    Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinuclear localization of an intracellular binding protein related to the fibroblast growth factor (FGF) receptor 1 is temporally associated with the nuclear trafficking of FGF-2 in proliferating epiphyseal growth plate chondrocytes.
    Kilkenny DM; Hill DJ
    Endocrinology; 1996 Nov; 137(11):5078-89. PubMed ID: 8895382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
    Marek L; Ware KE; Fritzsche A; Hercule P; Helton WR; Smith JE; McDermott LA; Coldren CD; Nemenoff RA; Merrick DT; Helfrich BA; Bunn PA; Heasley LE
    Mol Pharmacol; 2009 Jan; 75(1):196-207. PubMed ID: 18849352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.